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Background: Paracetamol’s (APAP) mechanism of action suggests the implication of 
supraspinal structures but no neuroimaging study has been performed in humans.
Methods and results: This randomized, double-blind, crossover, placebo-controlled trial in 
17 healthy volunteers (NCT01562704) aimed to evaluate how APAP modulates pain-evoked 
functional magnetic resonance imaging signals. We used behavioral measures and functional 
magnetic resonance imaging to investigate the response to experimental thermal stimuli with 
APAP or placebo administration. Region-of-interest analysis revealed that activity in response 
to noxious stimulation diminished with APAP compared to placebo in prefrontal cortices, insula, 
thalami, anterior cingulate cortex, and periaqueductal gray matter.
Conclusion: These findings suggest an inhibitory effect of APAP on spinothalamic tracts 
leading to a decreased activation of higher structures, and a top-down influence on descending 
inhibition. Further binding and connectivity studies are needed to evaluate how APAP modulates 
pain, especially in the context of repeated administration to patients with pain.
Keywords: paracetamol, nociception, fMRI, pharmacology, pain
What is really known about this subject?
The mechanism of action of paracetamol (APAP) is complex and a central mechanism 
of action has been described to explain its analgesic effect. However, this has not been 
to date visualized by neuroimaging and brain areas involved in the analgesic effect of 
APAP have not been studied.
What this study adds?
APAP 1) decreases activation of higher structures involved in pain and in cognitive/
affective processing and 2) exerts a top-down influence on descending inhibitory path-
ways and midbrain neurotransmission. This functional magnetic resonance imaging 
(fMRI) study opens interesting avenues for research on the mechanism of action of 
APAP per se and beyond that, for the development of new non-opioid analgesics.
Introduction
APAP (acetaminophen), one of the most frequently prescribed analgesics worldwide, 
has been largely explored in preclinical, molecular, and clinical studies over the last 
2 decades. The findings of its central mechanism of action,1–4 the concept of APAP as a 
prodrug with analgesic APAP metabolites,5,6 the implication of serotonergic, opioidergic, 
vanilloid, cannabinoid receptors as well as calcium channels7–13 have transformed our 
view of APAP from a drug acting at the periphery to a complex molecule with spinal 
and supraspinal actions. Clinical studies in healthy volunteers have confirmed the central 
serotonergic activation4 and the reinforcement by APAP of descending inhibitory pain 
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pathways3 in order to obtain APAP analgesic effect. This pain 
inhibitory system comprises a network of cortical regions and 
brain stem nuclei, the periaqueductal gray matter (PAG) and 
the rostral ventromedial medulla (RVM) that project to the 
dorsal horn of the spinal cord.14–16 Both the PAG and RVM 
receive direct projections from the spinal dorsal horn and 
may control the ascending nociceptive input by a feedback 
mechanism.17,18 In the few missing pieces of the APAP mecha-
nism of action puzzle, so far there has been a limited number 
of neuroimaging studies with APAP in humans.
fMRI allows to elucidate pharmacodynamic effects of 
a drug on brain function by combining the administration 
of a drug with fMRI. A number of studies with analgesics 
have demonstrated the coupling between subjective pain 
intensity ratings and objective blood oxygen level-dependent 
(BOLD) responses measured in central structures.19–21 The 
brain regions found active with fMRI during an acute physi-
cal pain experience, the so-called “pain matrix”, are well 
documented.16 As pain is a subjective experience,22–24 some 
of these regions (dorsal anterior cingulate cortex [ACC], 
anterior insula) are also involved in the affective and unpleas-
ant component of acute physical pain, as well as in social 
pain.25,26 Among analgesics, opioids,27–32 non steroidal anti-
inflammatory drugs, aspirin and parecoxib33 and ketamine34 
have been studied by fMRI.
Considering the corpus of research on APAP pharmacol-
ogy at the central level and the fact that the cerebral signature 
of APAP during physical pain has not been studied yet, this 
fMRI trial has been designed and combines physical pain 
induction with APAP administration. This clinical trial in 
healthy volunteers aims to evaluate how APAP modulates 
pain-evoked fMRI signals and how cerebral structures of the 
pain matrix and the PAG, cornerstone of APAP mechanism 
of action, are involved in APAP antinociception.
Methods
study protocol
This randomized, double-blind, crossover, controlled trial in 
healthy volunteers took place in the Clinical Investigation 
Centre/Clinical Pharmacology Centre and in the Neuroim-
aging Department of the University Hospital of Clermont-
Ferrand, France, between January 9, 2012 and April 13, 
2012. The study was reviewed and approved by the French 
Institutional Review Board and by the French Drug Agency. 
It followed standardized ethical and safety Good Clinical 
Practice Guidelines, and procedures were in accordance with 
the Declaration of Helsinki. It was declared on clinialtrials.
gov (NCT01562704).
Volunteers
Participants were recruited through the database of the 
Clinical Pharmacology Centre of the University Hospital of 
Clermont-Ferrand, France. Male volunteers (to avoid pain 
thresholds variability due to menstrual cycle in females) were 
eligible if they were $18 years old, did not take analgesic 
or anti-inflammatory treatment in the last 7 days and were 
nonsmokers. Exclusion criteria included the following: a 
known hypersensitivity to APAP, concomitant pathologies, 
contraindications in the realization of the MRI without injec-
tion (claustrophobia, pacemaker, hearing aid, cerebral clip 
etc), consumption of alcohol and addiction to street drugs. 
Eligible volunteers were informed about the protocol and 
provided a signed informed consent.
study design
A detailed overview of the experimental design used for 
the fMRI experiments is given in Figure 1. Prior to fMRI 
experiments, the volunteers were familiarized (two sessions 
at 1-week interval) with the thermal stimulation and the fMRI 
procedures. The trial itself consisted of two randomized fMRI 
sessions 1 week apart, with APAP or placebo according to 
the randomization list established beforehand by a research 
assistant who was not involved in the trial. On the day of 
the experiment, volunteers were comfortably lying on the 
examination table of the MRI scanner with the thermode 
strapped on the dominant hand for thermal tests. The pain 
threshold, defined as the temperature where the stimulation 
becomes painful, was evaluated and the noxious stimulation 
temperature (ST) was defined as the pain threshold +3°C 
according to previous tests performed in our department. 
Baseline fMRI was recorded using the thermal stimula-
tion paradigm (described later). Each MRI session lasted 
40 minutes. Subjects were then randomized at T0 in APAP 
or placebo groups. Double-blinding was fully respected with 
the volunteers and the members of staff. A research nurse 
who was only involved in drug allocation was in charge of 
drug administration. fMRI data acquisition was then repeated 
at T0+100 minutes (T0+100) during the application of the 
same thermal stimulation paradigm. Perceived pain was 
evaluated at the end of each fMRI session, at baseline and 
T+100 with a numeric pain rating scale ranging from 0 – no 
pain to 10 – maximal pain. Volunteers were then discharged 
after a clinical examination and came back a week later for 
the second period of the fMRI trial and were administered 
APAP or placebo in a crossover design.
The double-blind, randomized, and crossover design 
of this study was chosen in order to be able to discard all 
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3855
The brain signature of paracetamol in healthy volunteers
Pre screening 
Training 1
Selection
Training 2
Period 1
Placebo
Wash out: 
7 days
Placebo
T0
WP** WP**
PT/* PT/** *Treatment
administration
APAP 2 g or placebo
Outside of the MRI
Treatment
administration
APAP 2 g or placebo
Outside of the MRI
T0–60 min T0+100 min T0T0–60 min T0+100 min
APAP 2 g
Period 2
APAP 2 g
Figure 1 chronology of the study.
Notes: PT: determination of pain threshold with Thermotest pathway (Medoc ltd, ramat Yishai, israel). *Pain stimulation following the pain paradigm with Thermotest 
pathway (Medoc) and acquisition of data with fMri 3 Tesla (recording session duration: 40 minutes). Waiting period** outside from the Mri.
Abbreviations: aPaP, paracetamol; min, minute(s); fMri, functional magnetic resonance imaging; Mri, magnetic resonance imaging.
variable environmental factors, placebo analgesia, and 
have the subjects as their own controls. Such a clinical trial 
will isolate pure drug effects if expectations and beliefs 
of the subject are identical at each session to avoid any 
bias. The second test after administration of APAP was 
set at T0+100 based on published data on oral APAP with 
a maximal analgesic effect at 90–100 minutes3 and also 
to allow the patient some time out of the MRI scanner to 
limit fatigue and poor compliance. The main outcome of 
the study was the impact of APAP compared to placebo 
on BOLD fMRI activity by the analysis of the regions-of-
interest (ROI).
randomization
Patients were randomized in the APAP group (2 g of oral 
APAP in four capsules of 500 mg APAP each) or in the 
placebo group (four capsules of 500 mg lactose each). Ran-
domization was done according to the randomization list 
that had been established beforehand by a clinical research 
assistant who was not on site and not involved in the trial. 
Double-blinding was fully respected. Treatments were pre-
pared in the Central Pharmacy of the University Hospital with 
double-blinding according to Good Pharmaceutical Practice 
guidelines. APAP and placebo looked alike (red and white 
capsules). Randomization was done by blocks of four but 
this information was not known by the team.
evoked thermal pain stimulation
Thermal stimulation was delivered using a 25×25 Medoc 
TSA-II thermal sensory analyzer, contact heat-evoked 
potential stimulator (Medoc Ltd, Ramat Yishai, Israel).35,36 
An event-related protocol was used to apply contact heat 
stimuli to the thenar of the right hand (dominant hand, all 
volunteers were right-handed) during simultaneous fMRI 
acquisition. The thermode was comfortably applied on the 
thenar to avoid artifacts when moving the thermode during 
measurements. The thermode remained at the same site 
during each block of stimulation and no sensitization of the 
hand was observed in the feasibility study we carried out 
before the trial.
The stimulation paradigm (Figure 2) consisted of 20 cycles 
with 5-second stimuli at ST (ST had been determined before-
hand for each volunteer at the start of each period) followed 
by 15 seconds at the temperature of 32°C for a global dura-
tion of 8 minutes.
fMri data acquisition
fMRI experiments were carried out on a General Electric 
Discovery MR 750 3.0 T using a 32-channel head coil with 
subjects lying supine. Initial localizer images were acquired 
in three planes as a reference for slice positioning for 
?????????????????????????????????°???????????????????
???????? ???????????????????????????????????????????°?
???????? ???????????????????????????????????????????°?
×?????????
Figure 2 Thermal pain paradigm used in the fMri trial.
Abbreviation: fMri, functional magnetic resonance imaging.
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subsequent fMRI studies. A standard whole-brain gradient 
echo planar imaging sequence was used for the functional 
scans (repetition time =3,000 ms; echo time =30 ms; 160 vol-
umes field of view =240×240 mm2, matrix =128×128, voxel 
size =1.8×1.8×3.6 mm3, acquisition time =8 minutes). A high-
resolution volumetric three-dimensional (3D) T1-weighted 
acquisition was performed, for anatomical overlay of activa-
tion, in the same session as the functional scans: 3D brain vol-
ume imaging (repetition time =9.96 ms, echo time =4.1 ms, 
inversion time =400 ms, field of view =240×240 mm2, 
matrix =512×512, voxel size =1×1×1.2 mm3, acquisition 
time =3 minutes 22 seconds). To achieve synchronization, the 
trigger output of the scanner was used to initialize the fMRI 
paradigm and triggers from contact heat-evoked potential 
stimulation and the scanner were recorded together. fMRI 
sequences were assessed in the following order: anatomical 
scout, 3D brain volume, fMRI BOLD sequence echo planar 
imaging (thermal stimulation).
fMri data analysis
The neuroimaging data were preprocessed and analyzed 
using SPM8 (Statistical Parametric Mapping, Version 8; 
Wellcome Department of Imaging Neuroscience, London, 
UK), in Matlab 7.12 (MathWorks). Co-registration of T1 
anatomical images was performed prior to spatial normal-
ization into the MNI space. Functional images were first 
preprocessed with slice-time correction, and motion correc-
tion by realigning all images to the first image. The motion 
correction parameters were examined for each individual 
and instantaneous movement was always less than a third 
of the voxel size. The BOLD images were then spatially 
normalized into the MNI space using trilinear interpolation, 
with the normalization parameters determined during the 
normalization of the structural images. Subsequent spatial 
smoothing using isotropic 8 mm full width at half maximum 
Gaussian kernel was applied to the functional images to 
increase signal-to-noise ratio. A high pass temporal filter 
(cut-off 128 seconds) and correction for autocorrelation 
between successive scans were applied to the time series 
(AR1). On the basis of a priori hypotheses regarding the 
involvement of the ACC, insula, prefrontal cortices, thala-
mus, and PAG in the mechanism of action of APAP, we uti-
lized structurally defined ROI analyses to examine between 
group differences in neural activity in these regions during 
thermal pain stimulus.
For ROI extraction and beta analysis, we employed a 
block design with two conditions (baseline and stimulus). 
To determine those brain regions encoding pain intensity, 
we performed a whole-brain second-level statistical para-
metric maps of the t statistic (SPM{t}) analysis including 
all subjects and all functional scans obtained at baseline for 
both examinations (weeks 1 and 2), prior to drug intake. 
This allowed both to validate baseline pain matrix activa-
tion and to define the ROI in which beta extraction would 
be performed. The following ROI were defined using the 
Marsbar tool in SPM8: PAG, ACC, insula, prefrontal corti-
ces, and thalami. Beta extractions were then performed with 
the contrast stimulation-baseline, in order to assess group 
differences in neural activity in these regions during thermal 
noxious stimulus. Beta extraction corresponds to the value 
of the contrast in a selected ROI. It therefore corresponds 
to the estimate of the stimulus response compared to resting 
state, as it is an estimation of the effect of the BOLD signal 
in the ROI. Performing a beta extraction in a selected ROI 
allows to obtain an averaged beta value for the entire ROI. 
This extraction method allows to reduce the noise signal and 
therefore leads to an increase of the signal-to-noise ratio that 
facilitates stimulus response detection.
statistical analysis
Previous pilot fMRI studies with analgesics, opioids, and 
non-opioids include a variable number of subjects.32,33,37 
A double-blind, crossover, controlled fMRI study with non-
opioids included 14 subjects27 and an APAP pharmacological 
study with cerebral-evoked potentials included 12 subjects.35 
Considering these data, the estimated number of subjects was 
16, and taking into account potential dropouts, 20 patients 
had to be included.
Statistical analysis was performed using Stata software, 
version 13 (StataCorp LP, College Station, TX, USA). The 
tests were two-sided, with a type I error set at α=0.05. The 
characteristics of patients between groups were compared 
using Student’s t-test or Mann–Whitney test according 
to t-test hypotheses (assumption of normality studied by 
Shapiro–Wilk test and homoscedasticity by Fisher–Snedecor 
test) for quantitative parameters and using Fisher’s exact test 
for categorical factors. Beta values, presented as the mean ± 
associated standard deviation, were compared between 
groups using random-effects models for crossover designs. 
These models used the delta values as the dependent variables 
and included period, group, sequence, ROI, and possible 
carryover as fixed effects. In these models, we always con-
sidered random subject effects (random intercept and slope). 
The residual normality was checked for all models presented 
in this article. Random-effect models were performed to 
consider between and within subject variability (several 
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ROI measures for each subject) rather than averaging fMRI 
signals from different ROI. These models allowed to study 
the correlation between fMRI signals and the pain intensity 
considering pain intensity as a fixed effect.
BOLD response amplitude and perceived pain intensity 
were tested for a significant decrease between placebo and 
APAP sessions and between the two portions of the experi-
ment, baseline and drug administration. Significance was 
tested with a paired one-tailed Student’s t-test at P,0.05. 
BOLD response amplitudes to each stimulus were pooled 
(averaged) across subjects to achieve adequate signal-to-
noise for the parameter estimation.
Results
Twenty healthy right-handed males were eligible, three did 
not meet the inclusion criteria and 17 (22.7±3.2 years old) 
were randomized and analyzed. The flowchart is presented 
in Figure 3.
Psychophysics
The ST was not significantly different between both ses-
sions (47.1°C±2.1°C APAP, 46.3±2.4 placebo). During the 
overall fMRI experiment, APAP did modulate significantly 
(P,0.001) the mean pain ratings on the numerical scale 
evoked by the thermal stimulation (T0: 6.0±1.2; T100: 
3.6±0.8) compared to placebo that did not diminish pain (T0: 
5.8±1.1; T100: 5.6±1.1). APAP reduced the behavioral pain 
score from moderate/strong to mild pain.
fMri results
During acute pain stimulation, robust BOLD signals were 
seen in cortical regions typically involved in pain processing. 
These areas included the prefrontal cortices, ACC (anterior, 
medium, and dorsal), insula, thalamus, and PAG. Figure 4 
shows corresponding group activation maps during acute 
thermal pain.
Brain pain activation at baseline for both sessions was 
similar, making these groups comparable at the beginning of 
the sessions and making results methodologically reliable. 
Corresponding Talairach coordinates, t-scores, cluster sizes, 
and Broadmann areas are given in detail in Table 1.
Overall diminution between T0 and T100 was sig-
nificantly different between placebo and APAP (β =0.89 
vs -0.032, P=0.001). Comparisons between the APAP 
Enrollment Assessed for eligibility (n=20)
Randomized (n=17)
Allocation
Follow-up
Analysis
Analyzed (n=17) Analyzed (n=17)
Excluded (n=3)
Not meeting inclusion criteria (n=3)
Allocated to intervention (n=17)
Received allocated intervention (n=17)
Allocated to intervention (n=17)
Received allocated intervention (n=17)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Figure 3 Flowchart of the study.
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3858
Pickering et al
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
???
???
??
??
?
?
?
??
???
???
???
???
???
???
???
???
Fi
gu
re
 4
 P
ai
n 
m
at
ri
x 
at
 b
as
el
in
e 
sh
ow
in
g 
ac
tiv
at
io
n 
of
 le
ft 
an
d 
ri
gh
t 
pr
ef
ro
nt
al
 c
or
tic
es
, d
or
sa
l a
nt
er
io
r 
ci
ng
ul
at
e 
co
rt
ex
, l
ef
t 
an
d 
ri
gh
t 
in
su
la
, t
ha
la
m
us
, a
nd
 p
er
ia
qu
ed
uc
ta
l g
ra
y 
m
at
te
r.
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3859
The brain signature of paracetamol in healthy volunteers
and placebo groups showed that significant diminished 
activations were observed for APAP at T100 in prefrontal 
cortices (P=0.006 and 0.002 left and right, respectively), 
ACC (P=0.02, 0.004, and 0.002 for anterior, medium, and 
dorsal, respectively), insula (P=0.001 and P,0.001 left 
and right, respectively) and thalami (P=0.007 and 0.003 
for left and right, respectively). The diminution was not 
significant in the PAG (P=0.54), Figure 5. The correlation 
between fMRI signal for APAP diminution of activation 
(T100–T0) and the diminution of pain intensity was signifi-
cant for APAP (P=0.002) and not for placebo. The imaging 
results are therefore consistent with the behavioral analgesic 
effects of APAP.
Discussion
This trial, for the first time, visualizes the central effect of 
APAP in antinociception through neuroimaging. The study 
provides evidence in healthy subjects that APAP reduces the 
pain-related BOLD signal responses arising from peripheral 
noxious thermal stimulation, in several brain areas of the pain 
matrix. However, a limitation of the study is that it does not 
allow to differentiate between a peripheral and a central mecha-
nism of action as both could induce changes in the pain matrix. 
The reduction of perceived pain intensity scores simultaneous 
with the reduction in pain-related activity is consistent with 
the observed changes in BOLD signal resulting from the anal-
gesic effect of APAP. This point is important as an analgesic 
treatment may as part of its primary effect reduce or increase 
the BOLD signal by reducing or increasing neuronal activity/
local metabolic consumption.21 Compared to placebo, APAP 
significantly reduces the pain-related BOLD signal responses 
arising from the noxious thermal stimulation in the selected 
ROI, insula, ACC, thalamus, and prefrontal cortices. This 
suggests an inhibitory effect of APAP on spinothalamic tracts 
leading to a decreased activation of higher structures and a 
resulting anti-nociceptive effect of APAP. Some of these brain 
areas, dorsal ACC, and insula are also described to be involved 
in psychological and cognitive-emotional processes.16,26 An 
fMRI study38 found that APAP reduced neural responses to 
social rejection in these brain regions, demonstrating an over-
lap between social and physical pain. A recent cluster trial 
has also shown that APAP significantly reduces agitation and 
behavioral or psychological symptoms in patients with com-
munication disorders with a beneficial effect on well-being, 
with a probable impact on physical pain but also on other 
components of pain.39
This study also demonstrates some degree of deactivation 
of the PAG with APAP but does not reach the level of signifi-
cance set in our study. The PAG is known to have a pivotal 
role in the descending pain modulatory pain system17–40,41 
with top-down influences between higher centers from the 
cingulo-frontal cortex to the PAG and RVM downward to 
the spinal cord. The PAG is also an important projection 
site of ascending pain pathways that might have a role in 
pain modulation distinct from descending projections in the 
spinal cord.42 We suggest a number of hypotheses to explain 
our findings. Firstly, a covariation between the activity in the 
dorsal ACC and the PAG has been demonstrated in placebo 
analgesia and opioid analgesia, leading to opioid release 
within the brain stem.37 White matter tracks between ACC 
and PAG have also been described suggesting an anatomical 
support to the link between ACC and PAG,43 and neuro-
pharmacological evidence has suggested that corticobulbar 
neurons in the ACC directly or indirectly excite the PAG.9 
Our findings confirm a sort of continuum in APAP effect 
from higher centers to the PAG but with lesser impact 
than has been observed with morphine.15 Considering that 
the ACC and the PAG are very rich in opiate receptors, 
a weak opioidergic effect of APAP cannot be discarded and 
this corroborates a number of preclinical and clinical stud-
ies, discussing contradictory findings on the implication of 
opioidergic mechanisms in APAP mechanism of action. 
A clinical study in healthy volunteers35 using APAP and 
naloxone with cerebral-evoked potential suggested a possible 
but weak effect of opioid mechanisms in this context.
Table 1 coordinates of the regions of interest
Region TAL coordinates
X Y Z
cingulate gyrus
anterior -12 20 40
Middle 10 8 42
Posterior 16 -20 38
Prefrontal cortex
left
rOi 1 -20 56 10
rOi 2 -30 54 -8
right
rOi 1 30 46 -14
rOi 2 48 36 -12
insula
left -36 -2 0
right 38 -8 6
Pag 4 -36 -10
Thalamus
left -16 -17 11
right 18 -16 10
Abbreviations: fMri, functional magnetic resonance imaging; Pag, periaqueductal 
gray matter; rOi, regions-of-interest; Tal, Talairach coordinates.
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Figure 5 rOi analysis performed on physical pain regions revealed anti-nociceptive effect of aPaP compared to placebo.
Notes: Bar graphs demonstrate the β-values of aPaP deactivation (T+100 minutes . baseline) and placebo deactivation (T+100 minutes . baseline) extracted from each cluster. 
β-values associated with APAP differed significantly from the β-values associated with placebo in all regions (prefrontal cortices left and right [lPrc, rPFc], anterior cingulate 
cortex [acc], anterior [a], medium [m], dorsal [d]), insula left and right (lin, rin), and thalamus left and right (lTh, rTh) but in the periaqueductal gray matter (Pag).
Abbreviations: rOi, regions-of-interest; aPaP, paracetamol.
Secondly, the PAG is in a physiological continuum with RVM 
neurons that have been classified as on, off, and neutral cells. 
We suggest that the maintained partial activation of the PAG 
enables release of neurotransmitters and endogenous opioids 
that exert their anti-nociceptive action through the synapses of 
the RVM system, a mechanism similar to the one shown for 
morphine.18,44 APAP might have a direct effect and activate 
PAG off cells and disinhibit RVM off cells or may activate 
PAG and RVM on cells to exert their anti-nociceptive effect on 
dorsal horn transmission neurons. One of the key neurotrans-
mitters involved directly or indirectly in APAP mechanism of 
action is serotonin4,11,12 and serotonin receptors located at brain 
stem level, in combination with other mediators,2,11 play a role 
in the analgesic effect of APAP. Spinal serotonin receptors 
contribute to descending anti-nociceptive influence induced 
by stimulation of the PAG.45,46 An RVM subpopulation of 
neutral cells is serotoninergic, has more variable effects, and 
possibly modulates the effects induced by on and off cells to 
contribute to descending inhibitory controls relaying through 
the activation of PAG and RVM.18 This may be a specificity 
of action of APAP, as serotonergic neurotransmission, which 
recruits many serotonergic receptors including 5-HT2A and 
5-HT2C47 in the PAG plays a critical role in the elaboration 
of antinociception and a link between spinal 5-HT(7) and A1 
receptors in the spinal cord has been shown to be relevant to 
antinociception by systemic APAP.48
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Thirdly, the stimulus we used was 3 degrees above pain 
threshold and corresponds to moderate to severe pain, rated as 
6/10 at baseline. APAP is recommended for mild to moderate 
pain (3 to 7) but in severe or moderate/severe pain, opiates 
should then be prescribed. Although the subjects report less 
pain after APAP, there is some residual pain (4±2) that may 
explain that PAG activation is partially maintained.
Finally, cortical areas that are not included in the pain 
matrix, other brain stem regions, parallel descending pain 
inhibitory pathways may also be involved in APAP mechanism 
of action, and bidirectional links between the brain stem and 
cortical areas have also been described. Connectivity studies 
and pharmacological trials using tagged 5HT antagonists4 
would help to decipher the implication of the serotonergic 
system in APAP analgesic effect. Reports show that APAP 
easily passes the blood–brain barrier, that the enzyme involved 
in AM404 synthesis (FAAH), as well as vanilloid and can-
nabinoid receptors and neuronal calcium channels are all 
widely distributed among supraspinal and spinal structures7–13 
emphasizing the need for central studies. Considering the 
recent observation that a single APAP dose may increase 
the transcription of efflux transporter genes such as P-gp at 
the blood–brain barrier and enhance their production in the 
course of 3 hours,49 a study with repeated doses of APAP 
would show if longer term impaired brain permeation may 
have consequences on neuroimaging of pain with APAP, 
and may even decrease the effect of APAP, as suggested in a 
recent study challenging the international recommendations 
of APAP in osteoarthritis.50
Conclusion
This trial visualizes for the first time by fMRI the supraspi-
nal effect of APAP after a peripheral stimulation. It shows 
the decreased activation of a number of brain structures 
involved in physical pain and in cognitive/emotional 
domains of pain. Linking the findings of this study to the 
mechanistic cascade of events described in the literature, we 
suggest a top-down phenomenon with an active engagement 
of the PAG for APAP mechanism of action and a specific 
action on the midbrain neurotransmission system. Further 
binding and connectivity studies are needed to evaluate 
how the analgesic effect of APAP relates to cerebral and 
descending modulation of pain, especially in chronic admin-
istration in patients.
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